Navigation Links
Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
Date:5/22/2012

LEXINGTON, Mass., May 22, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,182,818, entitled "Methods of Using Anti-TNF Antibodies for Treating Radiation Damage to the Digestive Tract."

This patent provides broad coverage for using topically administered anti-TNF antibodies to treat radiation induced damage to the digestive tract.  Importantly, the patent specifically covers treatment of radiation induced mucositis, which is a common side effect of radiation therapy for cancer that often limits the effective radiation dose a patient can tolerate.  Avaxia has active research and development programs for its oral antibody AVX-470 for use in gastrointestinal acute radiation syndrome (GI-ARS) and mucositis. 

"This new patent emphasizes the innovative nature and broad applicability of our AVX Oral Antibody technology platform," stated Barbara Fox, PhD, CEO of Avaxia.  "For many cancer patients, the side effect of mucositis becomes intolerable, which causes terrible discomfort and may limit the dose of radiation that the patient receives to fight the disease.  Also, effective treatments for radiation damage are an important need for responding to potential terrorist attacks involving radioactive substances. Much of the morbidity and mortality associated with total body irradiation is due to damage to the GI tract. We are actively working to prove that AVX-470 can reduce that damage."

Avaxia has a $2.9 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop its oral anti-TNF antibody, AVX-470, for GI ARS. The work under this current contract explores the potential for the antibody to be further developed into a medical countermeasure to mitigate gastrointestinal damage from radiation exposure.

About Avaxia Biologics, Inc.: Avaxia is developing orally administered antibody therapeutics that act locally within the gastrointestinal (GI) tract.  Antibodies are widely used as therapeutics, with nearly $50 billion in annual sales worldwide.  Ordinary antibodies are not administered orally because they are destroyed in the GI tract.  In contrast, Avaxia has developed proprietary antibodies that are stable in the GI tract.  AVX Oral Antibodies make diseases with targets in the GI tract accessible to antibody therapeutics for the first time.  Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity. 


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
4. Avaxia Biologics Barbara Fox Named one of Mass High Techs Women to Watch in 2012
5. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
6. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
7. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
8. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
9. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
10. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
11. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
(Date:5/9/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... has earned a spot on Forbes, "America,s ... ranked among 500 U.S. employers as well as in ... Services. The annual Forbes rankings ... of over 30,000 employees across 25 industries. The survey ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as ... production of the series is on hiking in American. Viewers can reconnect with America ... great benefits of hiking. , Many consumers have looked for an inventive new place ...
(Date:5/26/2017)... ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of ... Cross” is the creation of published authors, Bob and Margaret Massey. Bob Massey is ... is "panther quick and leather tough." His love for others is apparent in all ...
(Date:5/26/2017)... ... ... Jack: Against All Odds”: the story of Coach Cactus Jack and the impact he ... creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and pharmacy ... Walter and Jane have three adult children and a granddaughter. Walter and ...
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... California (PRWEB) , ... May 24, 2017 , ... ... through innovative medical image management and interpretation, has received U.S. Food and Drug ... , Nucleus.io is a web-based, scalable and secure cloud platform for medical image ...
Breaking Medicine News(10 mins):